Liver leiomyoma

Summary

Liver leiomyoma (MONDO:0004723) is a disease. A subtype of benign endocrine neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	liver leiomyoma
Mondo ID	MONDO:0004723
DOID	DOID:917
NCIT	C5753
UMLS	C1333968
MedGen	232276
Anatomy (UBERON)	UBERON:0002107
Is cancer (heuristic)	no

Also known as: hepatic leiomyoma · leiomyoma of liver · leiomyoma of the liver · liver leiomyoma

Disease family

This is a subtype of benign endocrine neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › benign endocrine neoplasm › liver leiomyoma

Related subtypes (13): liver lipoma, liver hemangioma, bile duct papillary neoplasm, benign carotid body paraganglioma, benign thyroid gland neoplasm, pineocytoma, hepatocellular adenoma, benign neoplasm of pituitary gland, benign neoplasm of parathyroid gland, benign neoplasm of adrenal gland, benign neoplasm of thymus, TMEM127-related tumor predisposition, MAX-related tumor predisposition

Subtypes (1): extrahepatic bile duct leiomyoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.